<p>泰利福公司（NYSE:TFX - 免費報告）- Needham  Company LLC 的股票分析師在 5 月 8 日星期五向投資者發佈了對泰利福股票的 2028 年第一季度每股收益預期。Needham  Company LLC 的分析師 M. Matson 預計這家醫療技術公司在該季度的每股收益將為 2.90 美元。Needham  Company LLC 目前對該股票給予 &#34;買入&#34; 評級，目標價為 147.00 美元。市場普遍預期泰利福當前全年的每股收益為 6.75 美元。Needham  Company LLC 還發布了泰利福 2028 財年的每股收益預期為 12.18 美元。</p>
<p>泰利福（NYSE:TFX - 獲取免費報告）最近在 5 月 7 日星期四發佈了季度財報。這家醫療技術公司報告該季度每股收益為 1.39 美元，超出市場普遍預期的 1.21 美元，超過 0.18 美元。泰利福的淨利潤率為 -35.88%，股本回報率為 13.29%。該公司該季度的收入為 5.483 億美元，而市場普遍預期為 5.3691 億美元。去年同期，該公司的每股收益為 1.44 美元。與去年同期相比，該公司的收入增長了 32.3%。泰利福已將其 2026 財年的指導目標設定為每股收益 6.250-6.550。</p>
<p>其他幾位分析師也對該股票發佈了報告。富國銀行將泰利福的目標價從 130.00 美元上調至 138.00 美元，並在週五的研究報告中給予公司 &#34;持平&#34; 評級。Zacks Research 在 4 月 28 日星期二的研究報告中將泰利福的評級從 &#34;強烈賣出&#34; 上調至 &#34;持有&#34;。Weiss Ratings 在 3 月 27 日星期五的報告中重申了對泰利福的 &#34;賣出（d）&#34; 評級。Raymond James Financial 在週五的研究報告中重申了 &#34;跑贏大盤&#34; 評級，並對泰利福的股票設定了 150.00 美元的目標價。最後，華爾街 Zen 在週六的研究報告中將泰利福的評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。三位股票研究分析師對該股票給予了買入評級，五位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;持有&#34;，共識目標價為 144.00 美元。</p>
<p><strong>閲讀我們對 TFX 的最新分析</strong></p>
<h2>泰利福價格表現</h2>
<p>NYSE:TFX 的股票在星期二開盤價為 129.92 美元。該公司的速動比率為 2.03，流動比率為 2.55，債務與股本比率為 0.82。該股票的市值為 57.5 億美元，市盈率為 -5.70，市盈增長比率為 0.96，貝塔係數為 0.82。該公司的 50 日移動平均線為 120.08 美元，200 日移動平均線為 116.73 美元。泰利福的 52 周低點為 100.18 美元，52 周高點為 139.67 美元。</p>
<h2>機構投資者對泰利福的看法</h2>
<p>幾家機構投資者和對沖基金最近買入和賣出了 TFX 的股票。Empowered Funds LLC 在第一季度將其在泰利福的持股增加了 15.8%。Empowered Funds LLC 目前擁有 1,684 股這家醫療技術公司的股票，價值 233,000 美元，此前在上個季度又增持了 230 股。Jane Street Group LLC 在第一季度將其在泰利福的持股增加了 42.6%。Jane Street Group LLC 目前擁有 6,343 股這家醫療技術公司的股票，價值 877,000 美元，此前在上個季度又增持了 1,895 股。美國世紀公司在第二季度將其在泰利福的持股增加了 32.7%。美國世紀公司目前擁有 13,640 股這家醫療技術公司的股票，價值 1,614,000 美元，此前在上個季度又增持了 3,360 股。Invesco Ltd. 在第二季度將其在泰利福的持股增加了 1.2%。Invesco Ltd. 目前擁有 135,516 股這家醫療技術公司的股票，價值 16,040,000 美元，此前在該期間又購買了 1,659 股。最後，EverSource Wealth Advisors LLC 在第二季度將其在泰利福的持股增加了 108.1%。EverSource Wealth Advisors LLC 目前擁有 1,003 股這家醫療技術公司的股票，價值 119,000 美元，此前在該期間又購買了 521 股。對沖基金和其他機構投資者持有該公司 95.62% 的股票。</p>
<h2>泰利福宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，該分紅於 3 月 31 日星期二支付。3 月 6 日星期五的股東獲得了每股 0.34 美元的分紅。該分紅的除息日期為 3 月 6 日星期五。這相當於每年 1.36 美元的分紅，收益率為 1.0%。泰利福的分紅支付比率目前為 -5.96%。</p>
<h2>影響泰利福的關鍵頭條新聞</h2>
<p>以下是本週影響泰利福的關鍵新聞：</p>
<ul>
<li>積極情緒：Needham  Company 重申了對泰利福的 <strong>買入</strong> 評級，並設定了 <strong>147</strong> 美元的目標價，同時預測 <strong>2028 財年每股收益為 12.18 美元</strong> 和 <strong>2028 年第一季度每股收益為 2.90 美元</strong>，顯示出對長期收益增長的信心。Needham  Company 泰利福估計報告</li>
<li>積極情緒：Citizens JMP 也提高了其收益預期，預測 <strong>2027 財年每股收益為 10.50 美元</strong> 和季度每股收益為 <strong>2.03 美元</strong>、<strong>2.62 美元</strong>、<strong>2.83 美元</strong> 和 <strong>3.05 美元</strong>，這表明分析師們認為未來有顯著的利潤擴張。Citizens JMP 泰利福估計報告</li>
<li>中性情緒：Truist Financial 重申了 <strong>持有</strong> 評級，但將其目標價從 <strong>135</strong> 美元上調至 <strong>143</strong> 美元，暗示適度的上行空間，但沒有強烈的看漲轉變。泰利福在 Truist Financial 的持有評級得到重申。</li>
</ul>
<h2>泰利福公司簡介</h2>
<p>（獲取免費報告）</p>
<p>泰利福公司是一家多元化的全球醫療技術提供商，專注於重症護理和外科手術。公司總部位於賓夕法尼亞州韋恩，設計、製造並分銷醫療專業人員在醫院、門診和其他場所使用的設備和解決方案。泰利福致力於提供支持複雜介入程序並改善患者結果的產品。</p>
<p>公司的產品涵蓋多個關鍵領域，包括介入泌尿學、呼吸與麻醉、外科、心臟護理、血管和原始設備製造商（OEM）解決方案。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比泰利福更好</li>
<li>Ubiquiti 的上升趨勢可以繼續，但不要急於購買</li>
<li>TMC 在海底打造新的電動車供應鏈</li>
<li>五月賣出，離開——從這三隻股票開始</li>
<li>在月球基地建成之前，這四家公司獲勝</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRGWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRGWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在泰利福嗎？</h2>
<p>在考慮泰利福之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而泰利福並不在名單上。</p>
<p>雖然泰利福目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

泰利福

<p>泰利福公司（NYSE:TFX）已收到 Needham & Company LLC 對 2028 年第一季度每股收益的預測，預計為 2.90 美元。該公司維持 “買入” 評級，目標價為 147.00 美元。泰利福最近的季度收益為每股 1.39 美元，超出預期。分析師的評級各異，其中三位為買入，五位為持有，一位為賣出。該股開盤價為 129.92 美元，市值為 57.5 億美元。公司還宣佈每股季度分紅為 0.34 美元</p>

<p>Teleflex Incorporated (NYSE:TFX - Free Report) - Stock analysts at Needham &amp; Company LLC issued their Q1 2028 earnings per share estimates for shares of Teleflex in a note issued to investors on Friday, May 8th. Needham &amp; Company LLC analyst M. Matson expects that the medical technology company will post earnings per share of $2.90 for the quarter. Needham &amp; Company LLC currently has a &#34;Buy&#34; rating and a $147.00 price target on the stock. The consensus estimate for Teleflex's current full-year earnings is $6.75 per share. Needham &amp; Company LLC also issued estimates for Teleflex's FY2028 earnings at $12.18 EPS.</p>
<div class="lb-trans"><p>泰利福公司（NYSE:TFX - 免費報告）- Needham  Company LLC 的股票分析師在 5 月 8 日星期五向投資者發佈了對泰利福股票的 2028 年第一季度每股收益預期。Needham  Company LLC 的分析師 M. Matson 預計這家醫療技術公司在該季度的每股收益將為 2.90 美元。Needham  Company LLC 目前對該股票給予 &#34;買入&#34; 評級，目標價為 147.00 美元。市場普遍預期泰利福當前全年的每股收益為 6.75 美元。Needham  Company LLC 還發布了泰利福 2028 財年的每股收益預期為 12.18 美元。</p>
</div><p>Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.21 by $0.18. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The firm had revenue of $548.30 million for the quarter, compared to the consensus estimate of $536.91 million. During the same period last year, the firm posted $1.44 earnings per share. The business's revenue was up 32.3% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS.</p>
<div class="lb-trans"><p>泰利福（NYSE:TFX - 獲取免費報告）最近在 5 月 7 日星期四發佈了季度財報。這家醫療技術公司報告該季度每股收益為 1.39 美元，超出市場普遍預期的 1.21 美元，超過 0.18 美元。泰利福的淨利潤率為 -35.88%，股本回報率為 13.29%。該公司該季度的收入為 5.483 億美元，而市場普遍預期為 5.3691 億美元。去年同期，該公司的每股收益為 1.44 美元。與去年同期相比，該公司的收入增長了 32.3%。泰利福已將其 2026 財年的指導目標設定為每股收益 6.250-6.550。</p>
</div><p>Several other analysts have also issued reports on the stock. Wells Fargo &amp; Company upped their price target on shares of Teleflex from $130.00 to $138.00 and gave the company an &#34;equal weight&#34; rating in a research report on Friday. Zacks Research raised Teleflex from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, April 28th. Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of Teleflex in a report on Friday, March 27th. Raymond James Financial reaffirmed an &#34;outperform&#34; rating and issued a $150.00 price target on shares of Teleflex in a research note on Friday. Finally, Wall Street Zen lowered Teleflex from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and a consensus price target of $144.00.</p>
<div class="lb-trans"><p>其他幾位分析師也對該股票發佈了報告。富國銀行將泰利福的目標價從 130.00 美元上調至 138.00 美元，並在週五的研究報告中給予公司 &#34;持平&#34; 評級。Zacks Research 在 4 月 28 日星期二的研究報告中將泰利福的評級從 &#34;強烈賣出&#34; 上調至 &#34;持有&#34;。Weiss Ratings 在 3 月 27 日星期五的報告中重申了對泰利福的 &#34;賣出（d）&#34; 評級。Raymond James Financial 在週五的研究報告中重申了 &#34;跑贏大盤&#34; 評級，並對泰利福的股票設定了 150.00 美元的目標價。最後，華爾街 Zen 在週六的研究報告中將泰利福的評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。三位股票研究分析師對該股票給予了買入評級，五位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;持有&#34;，共識目標價為 144.00 美元。</p>
</div><p><strong>Read Our Latest Analysis on TFX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 TFX 的最新分析</strong></p>
</div><h2>Teleflex Price Performance</h2>
<div class="lb-trans"><h2>泰利福價格表現</h2>
</div><p>Shares of NYSE:TFX opened at $129.92 on Tuesday. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. The stock has a market cap of $5.75 billion, a PE ratio of -5.70, a PEG ratio of 0.96 and a beta of 0.82. The company's fifty day moving average is $120.08 and its 200 day moving average is $116.73. Teleflex has a 52 week low of $100.18 and a 52 week high of $139.67.</p>
<div class="lb-trans"><p>NYSE:TFX 的股票在星期二開盤價為 129.92 美元。該公司的速動比率為 2.03，流動比率為 2.55，債務與股本比率為 0.82。該股票的市值為 57.5 億美元，市盈率為 -5.70，市盈增長比率為 0.96，貝塔係數為 0.82。該公司的 50 日移動平均線為 120.08 美元，200 日移動平均線為 116.73 美元。泰利福的 52 周低點為 100.18 美元，52 周高點為 139.67 美元。</p>
</div><h2>Institutional Investors Weigh In On Teleflex</h2>
<div class="lb-trans"><h2>機構投資者對泰利福的看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of TFX. Empowered Funds LLC raised its holdings in shares of Teleflex by 15.8% during the first quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company's stock valued at $233,000 after acquiring an additional 230 shares in the last quarter. Jane Street Group LLC boosted its holdings in Teleflex by 42.6% in the first quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company's stock valued at $877,000 after acquiring an additional 1,895 shares in the last quarter. American Century Companies Inc. boosted its holdings in Teleflex by 32.7% in the second quarter. American Century Companies Inc. now owns 13,640 shares of the medical technology company's stock valued at $1,614,000 after acquiring an additional 3,360 shares in the last quarter. Invesco Ltd. increased its position in Teleflex by 1.2% during the 2nd quarter. Invesco Ltd. now owns 135,516 shares of the medical technology company's stock valued at $16,040,000 after purchasing an additional 1,659 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in Teleflex by 108.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company's stock valued at $119,000 after purchasing an additional 521 shares during the period. Hedge funds and other institutional investors own 95.62% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近買入和賣出了 TFX 的股票。Empowered Funds LLC 在第一季度將其在泰利福的持股增加了 15.8%。Empowered Funds LLC 目前擁有 1,684 股這家醫療技術公司的股票，價值 233,000 美元，此前在上個季度又增持了 230 股。Jane Street Group LLC 在第一季度將其在泰利福的持股增加了 42.6%。Jane Street Group LLC 目前擁有 6,343 股這家醫療技術公司的股票，價值 877,000 美元，此前在上個季度又增持了 1,895 股。美國世紀公司在第二季度將其在泰利福的持股增加了 32.7%。美國世紀公司目前擁有 13,640 股這家醫療技術公司的股票，價值 1,614,000 美元，此前在上個季度又增持了 3,360 股。Invesco Ltd. 在第二季度將其在泰利福的持股增加了 1.2%。Invesco Ltd. 目前擁有 135,516 股這家醫療技術公司的股票，價值 16,040,000 美元，此前在該期間又購買了 1,659 股。最後，EverSource Wealth Advisors LLC 在第二季度將其在泰利福的持股增加了 108.1%。EverSource Wealth Advisors LLC 目前擁有 1,003 股這家醫療技術公司的股票，價值 119,000 美元，此前在該期間又購買了 521 股。對沖基金和其他機構投資者持有該公司 95.62% 的股票。</p>
</div><h2>Teleflex Announces Dividend</h2>
<div class="lb-trans"><h2>泰利福宣佈分紅</h2>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Friday, March 6th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. Teleflex's dividend payout ratio is presently -5.96%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，該分紅於 3 月 31 日星期二支付。3 月 6 日星期五的股東獲得了每股 0.34 美元的分紅。該分紅的除息日期為 3 月 6 日星期五。這相當於每年 1.36 美元的分紅，收益率為 1.0%。泰利福的分紅支付比率目前為 -5.96%。</p>
</div><h2>Key Headlines Impacting Teleflex</h2>
<div class="lb-trans"><h2>影響泰利福的關鍵頭條新聞</h2>
</div><p>Here are the key news stories impacting Teleflex this week:</p>
<div class="lb-trans"><p>以下是本週影響泰利福的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: Needham &amp; Company reiterated a <strong>Buy</strong> rating on Teleflex and set a <strong>$147</strong> price target, while projecting <strong>FY2028 EPS of $12.18</strong> and <strong>Q1 2028 EPS of $2.90</strong>, signaling confidence in longer-term earnings growth. Needham &amp; Company Teleflex estimate report</li>
<li>Positive Sentiment: Citizens JMP also raised its earnings expectations, forecasting <strong>FY2027 EPS of $10.50</strong> and quarterly EPS of <strong>$2.03</strong>, <strong>$2.62</strong>, <strong>$2.83</strong>, and <strong>$3.05</strong> for 2027, which suggests analysts see meaningful profit expansion ahead. Citizens JMP Teleflex estimate report</li>
<li>Neutral Sentiment: Truist Financial reaffirmed a <strong>Hold</strong> rating but lifted its price target to <strong>$143</strong> from <strong>$135</strong>, implying moderate upside without a strong bullish shift. Teleflex Hold rating reaffirmed at Truist Financial</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：Needham  Company 重申了對泰利福的 <strong>買入</strong> 評級，並設定了 <strong>147</strong> 美元的目標價，同時預測 <strong>2028 財年每股收益為 12.18 美元</strong> 和 <strong>2028 年第一季度每股收益為 2.90 美元</strong>，顯示出對長期收益增長的信心。Needham  Company 泰利福估計報告</li>
<li>積極情緒：Citizens JMP 也提高了其收益預期，預測 <strong>2027 財年每股收益為 10.50 美元</strong> 和季度每股收益為 <strong>2.03 美元</strong>、<strong>2.62 美元</strong>、<strong>2.83 美元</strong> 和 <strong>3.05 美元</strong>，這表明分析師們認為未來有顯著的利潤擴張。Citizens JMP 泰利福估計報告</li>
<li>中性情緒：Truist Financial 重申了 <strong>持有</strong> 評級，但將其目標價從 <strong>135</strong> 美元上調至 <strong>143</strong> 美元，暗示適度的上行空間，但沒有強烈的看漲轉變。泰利福在 Truist Financial 的持有評級得到重申。</li>
</ul>
</div><h2>Teleflex Company Profile</h2>
<div class="lb-trans"><h2>泰利福公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.</p>
<div class="lb-trans"><p>泰利福公司是一家多元化的全球醫療技術提供商，專注於重症護理和外科手術。公司總部位於賓夕法尼亞州韋恩，設計、製造並分銷醫療專業人員在醫院、門診和其他場所使用的設備和解決方案。泰利福致力於提供支持複雜介入程序並改善患者結果的產品。</p>
</div><p>The company's offerings span several key segments, including Interventional Urology, Respiratory &amp; Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.</p>
<div class="lb-trans"><p>公司的產品涵蓋多個關鍵領域，包括介入泌尿學、呼吸與麻醉、外科、心臟護理、血管和原始設備製造商（OEM）解決方案。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Teleflex</li>
<li>Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It</li>
<li>TMC Forges a New EV Supply Chain at the Bottom of the Sea</li>
<li>Sell in May and Go Away—Starting With These 3 Stocks</li>
<li>Before the Moon Base Gets Built, These 4 Companies Win</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比泰利福更好</li>
<li>Ubiquiti 的上升趨勢可以繼續，但不要急於購買</li>
<li>TMC 在海底打造新的電動車供應鏈</li>
<li>五月賣出，離開——從這三隻股票開始</li>
<li>在月球基地建成之前，這四家公司獲勝</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRGWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=TFX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Teleflex Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在泰利福嗎？</h2>
</div><p>Before you consider Teleflex, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮泰利福之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而泰利福並不在名單上。</p>
</div><p>While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然泰利福目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

研究分析師發佈了泰利福第一季度收益預測